Status:
COMPLETED
Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension
Lead Sponsor:
University of California, San Francisco
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18-100 years
Brief Summary
Pulmonary hypertension is a progressive and life threatening condition. It is characterized by severe remodeling of the pulmonary vessel wall, obstructive plexiform lesions, multi-focal thrombosis, an...
Eligibility Criteria
Inclusion
- Patient's + 18 years with suspected pre-capillary pulmonary hypertension
- Prescribed Endothelial - 1 receptor blocker
Exclusion
- Currently taking endothelium-active vasodilator therapy.
- Hemoglobin and / or hematocrit level blood the lower normal limit.
- Left ventricle dysfunction (LVEF \<50%)
- LV end-diastolic pressure \> 15 mmHg)
- Recent history (\<3 months) of pulmonary embolism
- Liver failure or abnormal liver function tests; aortic or mitral regurgitation or stenosis
- Current medication with endothelin-1 receptor antagonist, prostacyclin analogues or type 5 phosphodiesterase inhibitors.
- Subjects with conditions known to be associated with an increase in circulating endothelial microparticle numers, such as chronic renal failure (Creatinine Clearance \< 50 ml/min/m2) acute coronary syndromes and uncontrolled system hypertension.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00675051
Start Date
March 1 2008
End Date
February 1 2009
Last Update
October 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California
San Francisco, California, United States, 94143